<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804153</url>
  </required_header>
  <id_info>
    <org_study_id>HULPURO-2010-01</org_study_id>
    <secondary_id>2010-024331-16</secondary_id>
    <nct_id>NCT01804153</nct_id>
  </id_info>
  <brief_title>Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)</brief_title>
  <acronym>HULPURO</acronym>
  <official_title>Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Mesenchymal Stem Cells Use Derived From Adipose Tissue (ASC) for the Local Feminine Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <brief_summary>
    <textblock>
      Evaluate the feasability and security of the autologous ASC for the femenine stress urinary
      incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate safety of adipose derived stem cells to femenine urinary incontinence with local
      application
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the feasability and security of the autologous ASC for the feminine stress urinary incontinence</measure>
    <time_frame>16 weeks</time_frame>
    <description>compress test (number dthe changes daily) urethrocystoscopy (morphology of urethra)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using the SF-12 Questionnaire</measure>
    <time_frame>1, 4, 16, 24 weeks</time_frame>
    <description>SF-12 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 4, 16, 24 weeks</time_frame>
    <description>Data collection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Autologous expanded stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose-derived expanded stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-derived expanded stem cells</intervention_name>
    <description>Intralesional application ASC</description>
    <arm_group_label>Autologous expanded stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. -Signed informed consen

          2. -Good general state of health according to the findings of ythe clinical history and
             the physical examination

          3. -Postmenopausal or over 18 years old women taking highly effective contraceptives
             following the ICH (M3) EMA guide

          4. -Women having rejected de rehabilitation treatment or in which the treatment had
             failed

          5. -Genuine or combined stress urinary incontinence diagnosed with at least 1 year of
             evolution

        Exclusion Criteria:

          1. -Pregnant or lactating women

          2. -Active urine infection

          3. -Presenting an infravesical obstruction

          4. -Alcohol or other addictive substances abuse antecedents in the previous 6 months to
             the inclusion

          5. -Presenting any other malignant neoplasia unless it is a basocellar or a skin
             epidermoide carcinoma or presents antecedents of malignant tumours, unless they are in
             a remission phase for the previous 5 years

          6. -Cardiopulmonar illness that, in the investigator opinion, could be unstable or could
             be serious enough to drop the patient from the study

          7. -Any kind of medical or psychiatric illness that, in the investigator opinion, could
             be a reason to exclude the patient from the study

          8. -Subjects with congenital or aquired inmunodeficiencies, B and/or C Hepatitis,
             Tuberculose or Treponema diagnosed at the moment of inclusion

          9. -Anesthesic allergy

         10. -Major surgery or severe trauma in the previous 6 months

         11. -Administration of any drug under experimentation in the present or 3 months before
             recruitement
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Alonso Gregorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariano García-Arranz, PhD</last_name>
    <phone>0034 912071022</phone>
    <email>mgarciaa.hulp@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Alonso Gregorio, MD</last_name>
    <phone>0034 912071022</phone>
    <email>garavelos@terra.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano García-Arranz, PhD</last_name>
      <phone>0034 912071022</phone>
      <email>mgarciaa.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Sergio Alonso Gregorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariano García-Arranz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damián García Olmo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando de Miguel Pedrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Strasser H, Tiefenthaler M, Steinlechner M, Eder I, Bartsch G, Konwalinka G. Age dependent apoptosis and loss of rhabdosphincter cells. J Urol. 2000 Nov;164(5):1781-5.</citation>
    <PMID>11025769</PMID>
  </reference>
  <reference>
    <citation>Buckley BS, Lapitan MC; Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008. Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. Urology. 2010 Aug;76(2):265-70. doi: 10.1016/j.urology.2009.11.078. Epub 2010 Jun 11.</citation>
    <PMID>20541241</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Pinggera GM, Marksteiner R, Margreiter E, Plattner R, Klima G, Strasser H. Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol. 2007 Dec;52(6):1736-43. Epub 2007 May 22. Erratum in: Eur Urol. 2008 Nov;54(5):1208. Bartsch, Georg [removed].</citation>
    <PMID>17532554</PMID>
  </reference>
  <reference>
    <citation>Kwon D, Kim Y, Pruchnic R, Jankowski R, Usiene I, de Miguel F, Huard J, Chancellor MB. Periurethral cellular injection: comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology. 2006 Aug;68(2):449-54.</citation>
    <PMID>16904482</PMID>
  </reference>
  <reference>
    <citation>Cannon TW, Lee JY, Somogyi G, Pruchnic R, Smith CP, Huard J, Chancellor MB. Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology. 2003 Nov;62(5):958-63.</citation>
    <PMID>14624934</PMID>
  </reference>
  <reference>
    <citation>Praud C, Sebe P, Biérinx AS, Sebille A. Improvement of urethral sphincter deficiency in female rats following autologous skeletal muscle myoblasts grafting. Cell Transplant. 2007;16(7):741-9.</citation>
    <PMID>18019363</PMID>
  </reference>
  <reference>
    <citation>Becker C, Jakse G. Stem cells for regeneration of urological structures. Eur Urol. 2007 May;51(5):1217-28. Epub 2007 Jan 18. Review.</citation>
    <PMID>17254699</PMID>
  </reference>
  <reference>
    <citation>Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001 Apr;7(2):211-28.</citation>
    <PMID>11304456</PMID>
  </reference>
  <reference>
    <citation>Zhao W, Zhang C, Jin C, Zhang Z, Kong D, Xu W, Xiu Y. Periurethral injection of autologous adipose-derived stem cells with controlled-release nerve growth factor for the treatment of stress urinary incontinence in a rat model. Eur Urol. 2011 Jan;59(1):155-63. doi: 10.1016/j.eururo.2010.10.038. Epub 2010 Oct 26.</citation>
    <PMID>21050657</PMID>
  </reference>
  <reference>
    <citation>Kajbafzadeh AM, Elmi A, Payabvash S, Salmasi AH, Saeedi P, Mohamadkhani A, Sadeghi Z, Nikfarjam L. Transurethral autologous myoblast injection for treatment of urinary incontinence in children with classic bladder exstrophy. J Urol. 2008 Sep;180(3):1098-105. doi: 10.1016/j.juro.2008.05.057. Epub 2008 Jul 18.</citation>
    <PMID>18639289</PMID>
  </reference>
  <reference>
    <citation>Fu Q, Song XF, Liao GL, Deng CL, Cui L. Myoblasts differentiated from adipose-derived stem cells to treat stress urinary incontinence. Urology. 2010 Mar;75(3):718-23. doi: 10.1016/j.urology.2009.10.003. Epub 2009 Dec 6.</citation>
    <PMID>19969332</PMID>
  </reference>
  <reference>
    <citation>Lin G, Wang G, Banie L, Ning H, Shindel AW, Fandel TM, Lue TF, Lin CS. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy. 2010;12(1):88-95. doi: 10.3109/14653240903350265.</citation>
    <PMID>19878076</PMID>
  </reference>
  <reference>
    <citation>Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, Erickson J, Huard J, Chancellor MB. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jun;19(6):881-3. doi: 10.1007/s00192-007-0553-z.</citation>
    <PMID>18204978</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Pinggera GM, Marksteiner R, Margreiter E, Fussenegger M, Frauscher F, Ulmer H, Hering S, Bartsch G, Strasser H. Adult stem cell therapy of female stress urinary incontinence. Eur Urol. 2008 Jan;53(1):169-75. Epub 2007 Jul 23.</citation>
    <PMID>17683852</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Marksteiner R, Margreiter E, Pinggera GM, Colleselli D, Frauscher F, Ulmer H, Fussenegger M, Bartsch G, Strasser H. Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int. 2007 Nov;100(5):1081-5. Epub 2007 Aug 30.</citation>
    <PMID>17760890</PMID>
  </reference>
  <reference>
    <citation>Mitterberger M, Marksteiner R, Margreiter E, Pinggera GM, Frauscher F, Ulmer H, Fussenegger M, Bartsch G, Strasser H. Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patients. J Urol. 2008 Jan;179(1):226-31. Epub 2007 Nov 14.</citation>
    <PMID>18001790</PMID>
  </reference>
  <reference>
    <citation>Roche R, Festy F, Fritel X. Stem cells for stress urinary incontinence: the adipose promise. J Cell Mol Med. 2010 Jan;14(1-2):135-42. doi: 10.1111/j.1582-4934.2009.00915.x. Epub 2009 Oct 3. Review.</citation>
    <PMID>19799652</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, García-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. Epub 2003 May 20.</citation>
    <PMID>12756590</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Feminine stress urinary incontinence</keyword>
  <keyword>Autologous expanded stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

